EDNRA and ovarian cancer: Of clinical significance, the incorporation of an ETAR targeting compound to DDRi + PARPi-based regimens, blocking an adaptive circuit, further potentiates the olaparib therapeutic effect, impeding the HG-SOC metastatic relapse (Fig. 8), providing a glimpse into the safeguard function of ETAR signalling in ovarian cancer.